Haemostasis balance disorders in patients with essential hypertension.
This study was aimed at investigating haemostasis parameters in patients (pts) with arterial hypertension (AH) before any medical treatment and to correlate these findings with those in healthy normal Greek population 83 pts (48 m, 35 w) mean age 49.8 +/- 10.1 yrs, body mass index 23.4 +/- 1.5 with mild to moderate AH and 42 healthy volunteers matched for sex (24 m, 18 w), age 51.2 +/- 10.5 yrs and body mass index 22.8 +/- 1.46 were studied. Fibrinogen, vWF, plasminogen, ECLT, a2 antiplasmin, tPA-Ag, PAI-1 in all pts and in the control group were measured. Mean age and BMI did not significantly differ between the two groups. The hypertensive patients had significantly higher levels of fibrinogen (327.75 +/- 51.36 vs. 272.84 +/- 46.8 mg/dl), tPA-Ag (8.81 +/- 3.32 vs. 5.76 +/- 2.54 ng/ml) and PAI-1 (11.8 +/- 10.9 vs. 7.91 +/- 5.5 IU/ml), whereas a2 antiplasmin level was significantly lower (98.71 +/- 15.40 vs. 107.84 +/- 17.52%). No differences were found between hypertensives and normal subjects in vWF, plasminogen and ECLT. These preliminary data suggest that in pts with mild to moderate AH, before any medical treatment, there are significantly higher levels of fibrinogen, tPA-Ag and PAI-1 compared with normal volunteers, whereas there are significantly lower a antiplasmin levels. These findings indicate a disturbance in the haemostasis balance with hypercoagulability and fibrinolytic deficiency.
Makris
T K
TK
Depart. of Cardiology-Haemophilia Treatment Center, 2nd Regional Blood Transfusion Center, Laiko University Hospital, Athens, Greece.
Tsoukala
C
C
Krespi
P
P
Hatzizacharias
A
A
Gialeraki
A
A
Papargyriou
J
J
Votteas
V
V
Mandalaki
T
T
D000328:Adult; D001778:Blood Coagulation Disorders / Q000097:blood / Q000503:physiopathology*; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D006115:Greece / Q000453:epidemiology; D006487:Hemostasis; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000453:epidemiology / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D010958:Plasminogen / Q000378:metabolism; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D010959:Tissue Plasminogen Activator / Q000097:blood; D000979:alpha-2-Antiplasmin / Q000378:metabolism; D014841:von Willebrand Factor / Q000378:metabolism
D017395:Plasminogen Activator Inhibitor 1; D000979:alpha-2-Antiplasmin; D014841:von Willebrand Factor; D005340:Fibrinogen; D010958:Plasminogen; D010959:Tissue Plasminogen Activator